KRYS Stock Cash Flow Statements

Krystal Biotech Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Krystal Biotech Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31

operating activities
net income	38,334,000	35,733,000	45,479,000	27,179,000	15,569,000	932,000	8,692,000	80,747,000	-33,210,000	-45,297,000	-32,052,000	-29,850,000	-28,108,000	-49,965,000	-21,806,000	-15,590,000	-16,362,000	-15,812,000	-10,383,000	-9,610,000	-6,833,000	-5,341,000	-5,357,000	-4,272,000	-5,348,000	-4,111,000	-3,708,000	-2,755,000	-2,276,000	-2,150,000	-1,393,000
adjustments to reconcile net income to net cash from operating activities
depreciation	1,349,000	1,410,000	1,364,000	1,341,000	1,835,000	1,427,000																335,000	250,000	191,000	175,000	132,000	61,000	38,000	24,000	18,000	14,000
amortization (accretion) on marketable securities
amortization of operating lease right-of-use assets	194,000	224,000	191,000	188,000	186,000	182,000
stock-based compensation expense	14,119,000	13,478,000	13,356,000	13,316,000	13,156,000	9,299,000	9,853,000	8,312,000	11,331,000	10,437,000	9,552,000	9,059,000	8,189,000	6,430,000	5,145,000	3,666,000	4,195,000	2,313,000	570,000	1,356,000	807,000	539,000	323,000	278,000	325,000	313,000	302,000	278,000	147,000	65,000	58,000
realized gain on investments	-2,754,000	-1,502,000	-1,642,000	-1,568,000	-1,646,000	-1,213,000
other	76,000	614,000	-73,000	636,000	327,000	-238,000	3,839,000	-1,919,000	-1,766,000	-605,000	-538,000	-58,000	-31,000	-135,000
changes in operating assets and liabilities
accounts receivable	-8,179,000	1,486,000	-7,449,000	5,939,000	-56,769,000	-4,427,000	-32,724,000
inventory	880,000	-1,395,000	-6,521,000	-3,678,000	530,000	-2,238,000	-492,000
prepaid expenses and other current assets	19,000	-2,976,000		-104,000	-2,268,000	-264,000	-771,000	1,387,000	-1,197,000	-327,000	-1,342,000	183,000	28,000	820,000	-1,959,000	-552,000	54,000	1,312,000	-2,400,000	123,000	258,000	108,000
lease liability	-122,000	-136,000	-216,000	-211,000	-207,000	-199,000	-226,000	-223,000	-215,000	-165,000	-188,000	-173,000	-160,000	-126,000	-45,000	-65,000	-98,000	-77,000	850,000	-60,000
other long-term liabilities	834,000	534,000	658,000	173,000
accounts payable	4,123,000	906,000	-591,000	91,000	784,000	727,000	-222,000	-360,000	374,000	107,000	-938,000	-340,000	578,000	-554,000	937,000	455,000	-974,000	294,000	58,000	19,000	462,000	244,000	-369,000	-243,000	-170,000	583,000	-17,000	108,000	125,000	-104,000	-138,000
accrued expenses and other current liabilities	-1,294,000	3,695,000	7,483,000	1,942,000	1,128,000	-5,162,000	2,763,000	3,461,000	1,799,000	-3,465,000	2,157,000	540,000	463,000	2,013,000	-4,021,000	4,048,000	2,390,000	288,000	1,325,000	899,000	-181,000	262,000	-144,000	263,000	275,000	153,000	163,000	380,000	181,000	-80,000	-393,000
accrued rebates	4,233,000	10,601,000	7,259,000	7,812,000	10,444,000	5,312,000
accrued litigation settlement	0	-31,250,000		6,250,000	12,500,000	12,500,000				12,500,000
net cash from operating activities	52,729,000	30,969,000	52,843,000	58,857,000	-4,168,000	15,888,000					-22,329,000	-19,688,000	-43,059,000	-15,493,000	-20,900,000	-7,255,000	-10,129,000	-9,654,000	-8,024,000	-6,766,000	-5,066,000	-6,227,000	-7,046,000	-4,243,000	-4,209,000	-3,215,000	-3,518,000	-1,940,000	-1,618,000	-2,369,000	-2,127,000
capex	-1,972,000	-4,807,000	-801,000	-1,322,000	-1,019,000	7,196,000					-5,217,000	-20,985,000	-16,515,000	-2,684,000	-48,733,000	-7,921,000	3,539,000	142,000	-683,000	-3,684,000	-573,000	-206,000	-2,624,000	-462,000	-1,238,000	-1,332,000	-1,304,000	-832,000	0	0	-159,000
free cash flows	50,757,000	26,162,000	52,042,000	57,535,000	-5,187,000	23,084,000					-27,546,000	-40,673,000	-59,574,000	-18,177,000	-69,633,000	-15,176,000	-6,590,000	-9,512,000	-8,707,000	-10,450,000	-5,639,000	-6,433,000	-9,670,000	-4,705,000	-5,447,000	-4,547,000	-4,822,000	-2,772,000	-1,618,000	-2,369,000	-2,286,000
investing activities
proceeds from disposal of assets	0	435,000
purchases of property and equipment	-1,904,000	-6,204,000	-801,000	-1,046,000	-1,131,000	-1,260,000	-1,847,000	-1,781,000	-2,790,000	-5,381,000	-5,217,000	-14,056,000	-16,515,000	-17,191,000	-40,883,000	-20,991,000	-3,989,000	-2,473,000	-7,207,000	-4,182,000	-1,946,000	-1,508,000	-2,279,000	-1,175,000	-1,238,000	-1,707,000	-1,304,000	-832,000			-159,000
purchases of investments	-113,899,000	-137,806,000	-143,472,000	-112,532,000	-113,401,000	-88,335,000	-82,906,000	-105,901,000	-174,393,000	-145,576,000	-104,069,000	-67,457,000	-84,501,000	-62,754,000	-106,652,000
maturities of investments	105,278,000	88,806,000	60,495,000	79,250,000	95,179,000	63,615,000
net cash (used in) investing activities	-10,525,000	-54,769,000
financing activities
proceeds from exercise of stock options	1,796,000	1,462,000	2,428,000	3,365,000	10,638,000	15,969,000
taxes paid for employee tax withholding related to restricted stock units	0	-12,116,000	0	0	0	-4,181,000
taxes paid related to settlement of restricted stock awards	0	-1,812,000	0	0	0	-1,205,000	0	0	0	-749,000	0	0	0	-649,000
net cash from financing activities	1,796,000	-12,466,000	2,428,000	3,365,000	10,638,000	10,583,000	2,619,000	13,388,000	185,269,000	1,474,000	3,069,000	2,120,000	30,700,000	-542,000	202,072,000	1,508,000	-199,000	144,304,000	141,000	166,000	117,469,000	243,000	299,000	13,167,000	94,019,000	40,000	64,288,000	9,549,000	4,000	6,000	-693,000
effect of exchange rate changes on cash and cash equivalents	1,059,000	171,000	-594,000	286,000	-337,000	187,000	-140,000	12,000	8,000	-36,000
net increase in cash and cash equivalents	45,059,000	-36,095,000		28,180,000	-13,220,000	678,000		97,366,000				-32,311,000	-50,583,000	-71,943,000	54,632,000	-42,913,000	-72,645,000	133,903,000	-14,100,000	-9,309,000			-7,292,000	8,219,000			57,003,000	4,854,000
cash and cash equivalents at beginning of period	0	344,865,000		0	0	358,328,000		0	0	161,900,000		0	0	341,246,000		0	0	268,269,000		0	0	187,514,000		0	0	103,670,000	0	0	0	49,591,000
cash and cash equivalents at end of period	45,059,000	308,770,000		28,180,000	-13,220,000	359,006,000		97,366,000	135,130,000	140,745,000		-32,311,000	-50,583,000	269,303,000		-42,913,000	-72,645,000	402,172,000		-9,309,000	111,453,000	180,225,000		8,219,000	88,574,000	98,013,000	57,003,000	4,854,000	-5,415,000	47,228,000
supplemental disclosures of non-cash activities
unpaid purchases of property and equipment included in accounts payable and accrued expenses	-68,000	1,397,000		-276,000	112,000	8,456,000		105,000	-867,000	11,865,000		-6,929,000
initial recognition of right-of-use assets	-8,000	1,802,000									0	162,000	0	1,394,000												3,394,000
supplemental cash flow information
income taxes paid	13,458,000	400,000	515,000	3,148,000
accretion on marketable securities		-453,000		-431,000	-302,000	-802,000
gain from sale of priority review voucher							0
amortization of marketable securities
prepaid expenses and other assets
accrued legal settlement														25,000,000
proceeds from sale of priority review voucher							0
net cash from investing activities			-83,778,000			-25,980,000	-10,160,000	105,192,000	-15,957,000	3,563,000	-5,208,000	-14,743,000	-38,224,000	-55,908,000	-126,540,000	-37,166,000	-62,317,000	-747,000	-6,217,000	-2,709,000	-950,000	-1,305,000	-545,000	-705,000	-1,236,000	-2,482,000	-3,767,000	-2,755,000			-159,000
proceeds from issuance of common stock
net change in cash and cash equivalents
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
supplemental disclosures of non-cash investing and financing activities
unpaid purchases of property and equipment														14,507,000	-7,850,000	13,070,000	7,528,000	2,615,000	6,524,000	498,000	1,373,000	1,302,000	-345,000	713,000
supplemental disclosure of cash flow information
other non-current assets				-18,000	-23,000	52,000	-16,000	-158,000	156,000	-46,000	-119,000	-46,000	6,000	9,000
proceeds from issuance of common stock, net of offering costs
supplemental disclosures of non-cash investing activities
amortization
loss on disposal of fixed assets
non-cash interest expense															0	0	0	1,492,000													0
issuance of common stock, net of issuance costs							2,619,000
repayment of astra build-to-suit liability
adjustments to reconcile net income to net cash (used in) operating activities
depreciation and amortization								826,000	1,038,000	705,000	1,089,000	975,000	976,000	1,015,000	784,000	783,000	666,000	536,000	490,000	477,000
loss on disposals of fixed assets																				30,000			13,000	0
net cash (used in) operating activities								-21,226,000	-34,190,000	-26,156,000
proceeds from maturities of investments								112,874,000	161,226,000	154,520,000	104,078,000	66,770,000	62,792,000	24,037,000	20,995,000
issuance of common stock									185,269,000	2,223,000		2,120,000	30,700,000	107,000		1,508,000	-199,000	152,264,000	141,000	166,000	117,469,000	243,000	299,000	13,167,000	94,019,000	40,000	64,288,000	9,549,000
net (decrease) in cash and cash equivalents										-21,155,000
repayment of astra build to suit liability															0	0	0	-7,960,000
unpaid offering costs														24,000		-25,000	-178,000	214,000			110,000	22,000
prepaid rent																				0	0	-2,400,000
initial recognition of right-of-use assets and modification																336,000
purchases of short-term investments																			0	-12,000	-1,226,000	-1,967,000	-1,706,000	-2,218,000	-4,137,000	-512,000	-2,463,000	-1,987,000
proceeds from maturities of short-term investments																	1,233,000	1,726,000	990,000	1,485,000	2,222,000	2,170,000	3,937,000	2,688,000
purchases of long-term investments
increase in
amortization of right-of-use asset																						26,000	26,000	68,000	65,000	67,000
purchase of other noncurrent assets
net decrease in cash and cash equivalents																						-7,289,000				-5,657,000
prepaids and other current assets																							-426,000	-528,000	415,000	-352,000	-367,000	-17,000
other noncurrent liabilities																											48,000
deferred rent liabilities
decrease in
purchases of other noncurrent assets																										-263,000
issuance of preferred stock and preferred units																															0
unpaid purchase of property and equipment																										375,000
unpaid deferred offering costs																										155,000				1,000	-1,304,000
proceeds from the issuance of convertible promissory notes																															-1,000,000
proceeds from the issuance of related party convertible promissory notes
conversion of convertible promissory notes to preferred stock																															0
conversion of preferred stock to common stock																															0
unpaid construction-in-progress
conversion of preferred units to preferred stock
prepaids and other assets																														-118,000
issuance of common stock and common units																														6,000	-693,000
net increase in cash																														-2,363,000	-2,979,000
prepaid and other assets
cash at beginning of period																															0
cash at end of period																															-2,979,000
conversion of common units to preferred units
1.
prepaid research and development expenses

We provide you with 20 years of cash flow statements for Krystal Biotech stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Krystal Biotech stock. Explore the full financial landscape of Krystal Biotech stock with our expertly curated income statements.

The information provided in this report about Krystal Biotech stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.